Add to Calendar 8/26/2020 8:00:00 AM 8/27/2020 5:00:00 PM 2020 State of Possible Conference

Special thanks to our Platinum Sponsor Morgan Stanley

Registered attendees will receive an email with the subject line “Welcome to the State of Possible Conference 2020 - Event Access Link” from registrations@bizzabo.com.


The State of Possible Conference, MassBio's Annual Meeting, will now be hosted virtually on August 26-27, 2020. Featuring interactive networking and a groundbreaking viewer experience, this event will not be your average webinar.  

We will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks®, inspiring and engaging content in the style of a TED Talk.

"It's the Woodstock of Life Sciences, with all-star performers playing their greatest hits all on one stage.” – 2019 State of Possible Conference attendee
 
If you haven’t attended our State of Possible Conference before, it is the premier east coast life sciences conference. We have some of the brightest names in biotech talking about the issues impacting our industry, covering topics from the realities of precision medicine to advancing new drug targets faster.

To inquire about sponsorship opportunities, contact Laura Rudberg.

2020 State of Possible Conference Refund Policy

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
Online Conference, Link will be sent in advance of the event.
MassBio Immediate Past Chair & Partner at Third Rock Ventures
Abbie Celniker joined Third Rock in 2016 bringing 30 years of experience in R&D and senior leadership roles. Abbie focuses on the formation, development and strategy of our portfolio companies and has assumed active leadership roles in the following: Board member of Cedilla Therapeutics Chairman of the board and former interim chief executive officer of Rheos Medicines Board member and former interim chief executive officer of Goldfinch Bio Former president and chief executive officer of Sesen Bio Prior to joining the firm, she served as president and CEO of Eleven Biotherapeutics (now Sesen Bio) since 2011. Previously, Abbie was the president and CEO of Taligen Therapeutics from 2008 to 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion’s executive vice president, translational medicine. She has served as the global head of biologics of Novartis AG, the senior vice president of R&D strategy and operations of Millennium Pharmaceuticals (now Takeda) and the vice president of protein technologies of the Wyeth Research facilities. Abbie is a member of the MassBio board of directors, a member of the board of ImaginAb, where she was previously the chair, and a member of the scientific advisory board for Adimab. She is also a member of the board of directors of the nonprofit Unitio and T1D. She has a B.A. in biology from the University of California, San Diego, and a Ph.D. in molecular biology from the University of Arizona. Abbie loves doing jigsaw puzzles, but never looks at the picture on the box, and she once completed a 1000-piece puzzle that was solid white.

Brought to you by